RecruitingPhase 3NCT05613023
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
PACE-NODES. A Phase III Randomised Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Sponsor
Institute of Cancer Research, United Kingdom
Enrollment
1,128 participants
Start Date
Sep 9, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria11
- Aged ≥ 18 years at randomisation
- Histopathological confirmation of prostate adenocarcinoma with Gleason/ISUP grade group scoring within twelve months of randomisation (unless otherwise discussed with the CI or co-Clinical Leads)
- Patients planned for 12-36 months androgen deprivation therapy
- High risk localised prostate cancer as defined by
- Gleason 8-10 (grade groups 4 and 5) and/or
- Stage T3a/b or T4 and/or
- PSA \> 20ng/ml (or \>10 ng/ml for patients on 5-alpha reductase inhibitors)
- Multi-parametric MRI of the pelvis- to include at least one functional MRI sequence in addition to T2W imaging within twelve months of randomisation
- Radiological staging to exclude metastatic disease, prior to starting ADT, with one of the following: PSMA PET-CT, fluciclovine/choline PET-CT, whole-body MRI, bone scan, CT of chest, abdomen and pelvis (imaging method as per local practice/standard of care).
- WHO performance status 0-2
- Ability of research subject to give written informed consent
Exclusion Criteria8
- N1 or M1 disease
- PSA \>50ng/ml (or \>25ng/ml for patients on 5-alpha reductase inhibitors), unless PET-CT imaging has been performed to confirm N0M0 disease
- Previous active treatment for prostate cancer
- Patients where SBRT is contraindicated: prior pelvic radiotherapy, inflammatory bowel disease, significant lower urinary tract symptoms N.B. where patient has repeated imaging showing bowel in close apposition to target volumes that would make pelvic radiotherapy highly unlikely to be deliverable should be excluded.
- Contraindications to fiducial marker insertion, where used- including clotting disorders, or patients at high risk when stopping anticoagulation or antiplatelet medications
- Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artefacts and would make pelvic node planning more difficult.
- Patients who have had chemotherapy within 6 weeks of the start of radiotherapy.
- Life expectancy \< 5 years
Interventions
RADIATIONSBRT
Stereotactic Body Radiotherapy
Locations(42)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05613023
Related Trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT0678067052 locations